SCHEMBL5320922

SCHEMBL5320922

CCOC(=O)c1cnc(N)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CPB2 Q96IY4 1/20 0.48
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAOA P21397 1/20 0.47
ALDH1A1 P00352 3/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
P2RY12 Q9H244 11/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31050105 0.84 ALDH1A1 (0.61) CYP2C9CYP2C19ALDH1A1MAPK1TDP1
SCHEMBL337203 0.84 ALDH1A1 (0.61) CYP2C9CYP2C19ALDH1A1MAPK1TDP1
SCHEMBL710842 0.84 CYP2C9 (0.53) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL20589119 0.83 CYP2C9 (0.43) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL15351663 0.83 CYP2C9 (0.51) CYP2C9CYP2C19ALDH1A1MAPK1TDP1
SCHEMBL16421721 0.83 CYP2C9 (0.51) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL28383608 0.83 CHEK2 (0.58) CYP2C9CYP2C19LMNACYP1A2CYP3A4
SCHEMBL31108808 0.82 PDGFRB (0.48) ALDH1A1MAPK1L3MBTL1P2RY12
SCHEMBL362230 0.82 PDGFRB (0.48) ALDH1A1MAPK1L3MBTL1P2RY12
SCHEMBL31719406 0.82 DPP4 (0.50) CYP2C9CYP2C19ALDH1A1MAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022053010-A1 FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2022-03-17 WO disclosed
WO-2007086080-A2 NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS LIMITED (IN) 2007-08-02 WO disclosed
US-7071175-B1 Pyridine mercapto carboxylic acids as carboxypeptidase U inhibitors ASTRAZENECA AB (SE) 2006-07-04 US disclosed
EP-1180098-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2002-02-20 EP disclosed
WO-2000066557-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-11-09 WO disclosed